| dc.contributor.author | Curiel, DT | |
| dc.contributor.author | Tekant, Y | |
| dc.contributor.author | Ramirez, PJ | |
| dc.contributor.author | Vickers, SM | |
| dc.contributor.author | Yamamoto, M | |
| dc.contributor.author | Davydova, J | |
| dc.date.accessioned | 2021-03-05T19:45:56Z | |
| dc.date.available | 2021-03-05T19:45:56Z | |
| dc.date.issued | 2005 | |
| dc.identifier.citation | Tekant Y., Davydova J., Ramirez P., Curiel D., Vickers S., Yamamoto M., "Oncolytic adenoviral therapy in gallbladder carcinoma", SURGERY, cilt.137, ss.527-535, 2005 | |
| dc.identifier.issn | 0039-6060 | |
| dc.identifier.other | av_d0cdedeb-e9f2-420f-9b5a-7d13ed8c3e48 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/138027 | |
| dc.identifier.uri | https://doi.org/10.1016/j.surg.2004.12.014 | |
| dc.description.abstract | Background. Oncolytic adenoviral therapy is a promising new approach for cancer treatment. The aim of this study was to improve the conditionally replicative adenoviruses (CRAds) for gallbladder cancer therapy by modifying the fiber-knob region for infectivity enhancement and by incorporating tumor-specific promoters (TSPs) for enhanced specificity. | |
| dc.language.iso | eng | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | CERRAHİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Tıp | |
| dc.subject | Cerrahi Tıp Bilimleri | |
| dc.title | Oncolytic adenoviral therapy in gallbladder carcinoma | |
| dc.type | Makale | |
| dc.relation.journal | SURGERY | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 137 | |
| dc.identifier.issue | 5 | |
| dc.identifier.startpage | 527 | |
| dc.identifier.endpage | 535 | |
| dc.contributor.firstauthorID | 27704 | |
